NEPG: The net profit for the third quarter was 43.5245 million yuan, a decrease of 14.92%Zhitong·Oct 27, 2025 at 10:42 AM000597-1.04%
NEPG: The holding subsidiary has obtained approval for drug clinical trialsZhitong·Oct 8, 2025 at 08:34 AM000597-1.04%
NEPG: Chief Financial Officer Zhou Yana resigns due to health reasonsZhitong·Sep 1, 2025 at 12:21 PM000597-1.04%
NEPG: Net profit of 129 million yuan in the first half of 2025, a year-on-year decrease of 17.62%Zhitong·Aug 26, 2025 at 12:34 PM000597-1.04%
China Galaxy Securities: Cell gene therapy has entered the stage of result realization, and CXO is expected to benefit firstZhitong·Jun 13, 2025 at 12:04 AM300147-3.51%000597-1.04%
NEPG: The active pharmaceutical ingredient fosfomycin trometamol has received CEP certificationZhitong·Jun 4, 2025 at 12:42 PM000597-1.04%
NEPG: Subsidiary obtains drug registration certificate for L-carnitine oral solutionZhitong·Apr 16, 2025 at 11:22 AM000597-1.04%
NEPG: Fangda Steel has cumulatively increased its holdings in the company by 1.5175 million sharesZhitong·Apr 15, 2025 at 02:36 PM000597-1.04%
NEPG subsidiary obtains drug registration certificate for Levetiracetam extended-release tabletsZhitong·Apr 9, 2025 at 08:58 AM000597-1.04%
NEPG released its 2024 annual performance, with a net profit attributable to the parent company of 410 million yuan, an increase of 14.34%Zhitong·Apr 2, 2025 at 01:15 PM000597-1.04%
NEPG: The approval notice for the listing application of the chemical raw material drug Efevren has been receivedZhitong·Feb 14, 2025 at 10:46 AM000597-1.04%
NEPG plans to donate 10 million yuan to the earthquake disaster area in Dingri County, Shigatse City, TibetZhitong·Jan 8, 2025 at 11:11 AM000597-1.04%
Dongbei Pharmaceutical appointed Zhou Yana as Chief Financial OfficerZhitong·Dec 23, 2024 at 09:18 AM000597-1.04%
NEPG: The application for the listing of the raw material drug Empagliflozin has been approvedZhitong·Dec 18, 2024 at 11:21 AM000597-1.04%
NEPG: The listing application for the chemical raw material drug Empagliflozin has been approvedZhitong·Dec 18, 2024 at 11:20 AM000597-1.04%
